



Hartmut Döhner

Contact

Hartmut Döhner

Publications (5)

Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, Crysandt M, Jost E, Thol F, Heuser M, Götze K, Schlenk R, Salih H, Schittenhelm M, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kuendgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May A, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. *Eur J Haematol* 2024

Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Mol Cancer* 2013; 12:46.

Krönke J, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R, Döhner H, Späth D, Kapp-Schwörer S, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V, Kühn M, Rucker F, Holzmann K, Paschka P, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. *Blood* 2013; 122:100-8.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer* 2013; 12:19.

Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell* 2007; 12:501-13.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch